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ABSTRACT
Background: Patients with EGFR-mutated non-small-cell lung cancer benefit from 
EGFR tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be 
impaired by driver mutations in other genes.
Methods: Five hundred and fourteen consecutive patients with NSCLC of all 
stages were tested for EGFR-mutations by cobas® EGFR Mutation Test. Fluorescent 
in situ hybridization (FISH) for MET-amplification, immunohistochemistry (IHC) for 
MET- and ALK-expression, and Next Generation Sequencing (NGS) for concomitant 
driver mutations were performed on EGFR-mutated tumor samples from erlotinib-
treated patients.
Results: Thirty-six patients (7%) had EGFR-mutations, including 2 with intrinsic 
resistance mutation p.T790M together with the p.L858R sensitizing mutation and 1 
harboring the p.G719C/S768I double-mutation. Twenty-three patients had either 
locally advanced or advanced disease and received first-line erlotinib-treatment. 
Concomitant driver mutations were found in 15/21 (71%) of NGS-analyzed TKI-
treated NSCLCs, involving in 67% of cases TP53, in 13% CTNNB1, and in 7% KRAS, 
MET, SMAD4, PIK3CA, FGFR1, FGFR3, NRAS, DDR2, and ERBB4. No ALK-expression was 
found, whereas MET-overexpression and MET-amplification were observed in 5 and 4 
patients, respectively. Objective responses occurred in 17/23 patients (74%), 4 did 
not respond (17%), and 2 harboring a SMAD4-mutation (p.R135*(stop)) and a FGFR3-
mutation (p.D785fs*31), respectively, displayed mixed response with simultaneously 
progressing and responding tumors (8.7%). Thus, EGFR-mutated tumors harboring 
co-mutations were not less likely to respond.
Conclusion: Co-mutations in other cancer-driver genes (oncogenes or tumor 
suppressor genes) were frequent in EGFR-mutated NSCLCs and few cases harbored 
concomitant activating and resistance EGFR-mutations before TKI-treatment. Most 
co-mutations did not impact the response to first-line erlotinib-treatment, but may 
represent potential additional therapeutic targets.
INTRODUCTION
EGFR is a member of the ErbB family of 
transmembrane receptor tyrosine kinases (TKs) and 
upon ligand-binding and dimerization undergoes auto-
phosphorylation of its intracellular domain, resulting in 
recruitment of different adaptors and signal-transducers 
and activation of downstream signaling-pathways. 
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These especially include the RAS-RAF-MEK-
MAPK, the PI3K-AKT-PTEN-mTOR, and the STAT 
pathways, ultimately resulting in cancer-promoting 
effects, such as increased cell proliferation, survival, 
protein synthesis, migration, and angiogenesis [1]. 
Common gain-of-function mutations of EGFR, such 
as most of microdeletions in exon 19 and the point-
substitution p.L858R in exon 21, which together 
represent almost 90% of all EGFR-mutations, result 
in constitutive ligand-independent EGFR-TK activity 
and oncogenicity as well as increased affinity and 
sensitivity to the first- and second-generation EGFR-
TK inhibitors (TKIs) gefitinib, erlotinib and afatinib. 
These drugs are currently the standard of care first-line 
treatment for patients with advanced EGFR-mutated 
NSCLC, with higher response rate (RR) observed for 
patients with exon 19-microdeletions [1, 2]. Despite 
initial response to first-line EGFR-TKIs, most patients 
inevitably become resistant with median progression-
free survival (PFS) of 10-12 months. In up to 60% of 
cases, this is due to the emergence of the secondary 
p.T790M EGFR-mutation in exon 20, which also is an 
activating mutation, but possesses increased affinity for 
ATP, thereby competitively impeding the binding of 
reversible EGFR-TKIs to the EGFR ATP-binding pocket 
[3, 4]. The third-generation EGFR-TKI osimertinib is 
currently the standard of care for treating advanced 
EGFR-mutant NSCLC with p.T790M-positive acquired 
TKI-resistance.
Most of the activating EGFR-mutations occurring in 
non-small-cell lung cancer (NSCLC) before treatment are 
mutually exclusive with those in other oncogenic drivers. 
However, additional distinct driver alterations such as 
ALK-rearrangement, KRAS-mutations, PIK3CA-mutations, 
MET-amplification and others were recently reported to 
co-exist with EGFR-mutations in a small percentage of 
TKI therapy-naïve pulmonary adenocarcinomas (ADCs) 
[5–13]. A recent database study including 17664 lung 
cancer patients identified 2-3 concomitant driver mutations 
in almost 1% of these cases [6].
Importantly, the occurrence of co-mutations in 
EGFR itself or other cancer-drivers at diagnosis may 
potentially impair the efficacy of tyrosine-kinase-
inhibitors (TKIs) and partly explain why approximately 
10% of TKI-treated NSCLCs are intrinsically resistant [4].
Consequently, the evaluation of EGFR-mutations 
and ALK-rearrangements for selecting NSCLC patients 
treatable with first-line TKIs may not be sufficient to 
predict the response to these treatments. Thus, we 
examined the frequency of an extended panel of cancer-
relevant mutations that could potentially reduce the 
initial response to TKIs in a cohort of newly diagnosed, 
EGFR-mutated, advanced NSCLC of primarily ADC 
subtype. Additionally, we evaluated the response to 
erlotinib of EGFR-mutated tumors with or without co-
mutations.
RESULTS
EGFR-mutations and patients characteristics
Thirty-six (7%) of the 514 tested NSCLCs 
displayed EGFR-mutations, including two tumors with 
co-existing p.L858R and p.T790M mutations, one of 
which was from an operable patient. Of the 514 patients, 
283 (55.1%) had advanced stage or were not amenable 
for definitive local treatment because of poor pulmonary 
function. Twenty-three of these patients (8.1%) had 
tumors harboring activating EGFR-mutations and were 
treated with erlotinib, their individual characteristics 
are shown in Table 1 and histological subtype and type 
of EGFR-mutations in Table 2. Eighteen (78%) of the 
patients with EGFR-mutated tumors were females and 
five (22%) males, whereas in terms of smoking habit, 
18 (78%) were never/previous smokers and 5 (22%) 
current smokers. According to established criteria [14], 
the specimens from 20 of the EGFR-mutant cases (87%) 
were diagnosed as lung ADCs, based on the presence of 
acinar/papillary/micropapillary/solid epithelial structures, 
mucin production, and immunohistochemical markers (all 
were CK7+/TTF1+/CK5-/p40-), whereas one specimen 
(4%) was classified as SCC because of lack of mucin 
production and marker status (CK7-/TTF1-/CK5+/p40+). 
The specimens of the other two EGFR-mutant cases (9%) 
were classified on biopsies as most likely adenosquamous 
carcinomas (ADSC), based on the co-existence of cells 
with mucin production, keratinization and ADC/SCC 
immunohistochemical markers (CK7+/TTF1+/CK5+/
p40+). Seven patients had a single p.L858R mutation, 14 
an exon 19-microdeletion, one harbored the p.G719C/p.
S768I double mutation, one p.L858R combined with the 
intrinsic erlotinib-resistant p.T790M mutation, and one the 
unusual p.E746_R748del/p.A750P combination (Figure 
1A). Taken together, these results are consistent with the 
well-established notions that, regardless of ethnicity, the 
frequency of EGFR-mutations is higher among women, 
never/light smokers, and with NSCLC of ADC type, 
and that the exon 19-microdeletions and the p.L858R 
substitution in exon 21 are the most frequent EGFR-
mutations in NSCLC [1].
NGS findings
DNA for NGS was available from 21 of the 23 
EGFR-mutated cases (Table 2). Complete concordance 
was observed between EGFR-mutation-status by Cobas® 
EGFR Mutation Test and NGS. However, one sample 
identified by Cobas®Test as exon 19-microdeletion turned 
out to be an exon 19-insertion resulting in 6-amino-acid 
duplication (c.2213-2230dup, p.I744_K745insKIPVAI) 
by NGS analysis. Fifteen of the 21 NGS-analyzed cases 
displayed co-mutations in other cancer-relevant genes 
(Table 2), with TP53-mutations being the most represented 
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(n=10, 67%, subdivided in 7 missense mutations, 1 
intronic substitution, 2 previously unreported frameshift 
deletions). Other mutations were identified in CTNNB1 
(n=2, 13%), KRAS, FGFR1, FGFR3, MET, SMAD4, 
PIK3CA, NRAS, DDR2, ERBB4 (all n=1, 7%), with the 
latter 3 gene-mutations concomitantly present in the 
same tumor (patient 15, Table 2). The spectrum and 
pathogenic prediction of these co-mutations according to 
the catalogue of somatic mutations in cancer (COSMIC, 
http://cancer.sanger.ac.uk/cosmic) are indicated in Table 2.
FISH and IHC
None of the 23 EGFR-mutated cases showed 
expression of ALK-fusion protein. FISH and IHC for MET 
were feasible in 22 of the cases. We detected significant 
variation concerning average MET GCN per tumor cell 
nucleus (range 1.62-13.74; mean 3.81) and MET/CEN7 
ratio (range 0.74-4.58; mean 1.31), which is consistent 
with other recent results in treatment-naïve NSCLCs [11].
Two of the FISH-analyzed cases (9.1%) exhibited 
high-level MET gene-amplification concomitant with the 
p.L858R EGFR-mutation (Figure 1B-1D), while another 
case (4.5%) showed intermediate-level of MET GCN 
gain together with the above-mentioned p.G719C/p.
S768I double mutation. Additionally, the sample (4.5%) 
harboring the above-mentioned EGFR exon 19-insertion 
p.I744_K745insKIPVAI had low-level of MET GCN 
gain (Table 2). The remaining 18 cases (81.8%) were 
negative for MET-amplification. The 4 cases with MET-
amplification, regardless of the GCN increase level, 
showed MET-overexpression by IHC (Table 2, Figure 
Table 1: Individual characteristics and outcome of 23 EGFR-mutation positive, treatment naïve NSCLC patients 
treated with erlotinib
Patient no. Gender Age PS Smoking status Stage
Objective 
response to 
erlotinib
PFS 
(months)
OS 
(months)
1 Female 75 1 Never IIIA PR 24 24
2 Female 58 1 Current IV PR 19 41
3 Female 61 0 Never IV PR 5 7
4 Female 62 0 Previous IV PR 8 25
5 Female 76 1 Current IV PR 7 16
6 Female 81 0 Previous IIIA PR 20 50 (Alive)
7 Male 83 1 Never IV PR 18 29
8 Female 62 1 Never IV NC 10 47
9 Female 59 0 Previous IIIB PR 17 34
10 Female 50 0 Current IV NC 20 35
11 Female 83 1 Previous IV PR 17 32
12 Female 60 0 Never IV Mixed 15 21
13 Female 53 0 Never IV NC 14 23
14 Female 56 0 Current IV PR 8 28
15 Female 47 1 Previous IV PR 6 9
16 Female 82 2 Never IV PR 8 15
17 Female 81 1 Never IIIA PR 9 22
18 Male 67 1 Previous IV PR 8 17
19 Male 63 0 Previous IV NC 9 23
20 Female 63 0 Never IV CR 13 33
21 Female 59 1 Previous IV CR 8 19
22 Male 75 1 Previous IIIB PR 8 16
23 Male 49 1 Current IV Mixed 1 10
PS: WHO Performance status; CR: Complete response; PR: Partial response; NC: No change.
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Table 2: Histological subtype and biomarker status in 23 EGFR- mutation- positive NSCLC patients treated with 
erlotinib
Patient 
no.
NSCLC 
histotype
EGFR-mutations^
(c.: cDNA sequence; p.: 
protein sequence)
MET-
amplification§
MET protein 
overexpression§§
TP53 
mutation Other mutations
1 ADSC c.2573T>G, p.L858R
c.473G>T, 
p.R158L 
(pathogenic)
KRAS: c.35G>T, 
p.G12V 
(pathogenic)
2 ADC c.2155G>T, p.G719C + c.2303G>T, p.S768I
Intermediate-
level of 
amplification
3+ in 80% of 
tumor cells
c.503A>G, 
p.H168R 
(likely-
pathogenic)
3 ADC c.2573T>G, p.L858R
4 ADSC c.2573T>G, p.L858R High-level amplification
3+ in 100% of 
tumor cells
5 ADC c.2573T>G, p.L858R High-level amplification
3+ in 70% of 
tumor cells
6 ADC c.2239_2253del15, p.L747_T751delLREAT
Not enough 
cells for 
analysis
Not enough cells 
for analysis
7 ADC c.2239_2253del15, p.L747_T751delLREAT
c.723Cdel, 
p.S241fs* 
(unknown)
8 ADC c.2573T>G, p.L858R + c.2369C>T, p.T790M
9 ADC
c.2236_2244del9, p.E746_
R748del + c.2248G>C, 
p.A750P
MET:
c.3029C>T, 
p.T1010I 
(pathogenic)
10 ADC c.2213-2230dup, p.I744_K745insKIPVAI
Low-level 
amplification
3+ in 100% of 
tumor cells
c.463A>C, 
p.T155P 
(neutral)
11 SCC c.2235_2249del15, p.E746_A750delELREA
Not sufficient DNA 
for NGS analysis
12 ADC c.2573T>G, p.L858R
SMAD4: c.403C>T, 
p.R135* (stop) 
(pathogenic)
13 ADC Exon 19 del (by Cobas) Not sufficient DNA for NGS analysis
14 ADC c.2236_2250del15insTTA,p.E746-T750delinsL
c.734G>A, 
p.G245D 
(pathogenic)
15 ADC c.2235_2249del15, p.E746_A750delELREA
c.818G>T, 
p.R273L 
(pathogenic)
NRAS:
c.401C>T, p.A134V 
(unknown);
DDR2: c.1549G>C, 
p.G517R 
(unknown);
ERBB4: c.716C>T, 
p.S239P 
(pathogenic)
(Continued )
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1D). In addition, one EGFR-mutated tumor exhibited 
MET-overexpression without MET-amplification (Table 
2), suggesting other mechanisms increasing the receptor 
expression in this case.
Clinical outcomes
Among the 23 EGFR-mutated patients treated with 
erlotinib, 17 (74%) responded, 4 (17%) had no OR, and 2 
(9%) harboring a SMAD4-mutation (p.R135*(stop)) and 
a FGFR3-mutation (p.D785fs*31), respectively, showed 
mixed response with simultaneously progressing and 
responding tumor lesions (Tables 1 and 2). The above-
named tumor harboring the double p.L858R/p.T790M 
EGFR-mutation, did not respond to erlotinib, while another 
case with p.L858R did, despite concurrently harboring the 
p.G12V KRAS-mutation and p.R158L TP53-mutation. 
Median PFS was 8.8 months, 95%CI [7.3; 10.5] and OS 
was 23.3 months, 95%CI [20.1; 26.6] among all 23 patients 
harboring EGFR-mutations. No significant differences in 
PFS (8.5 months, 95%CI [7.7; 9.3] vs. 9.9 months, 95%CI 
[3.0; 16.7]) (p=0.56) or OS (23.3 months, 95%CI [20.5; 
26.2] vs. 22.8 months, 95%CI [7.2; 38.3]) (p=0.18) were 
observed when comparing EGFR-mutated tumors with 
or without concomitant genetic aberrations (Figure 2). 
However, 2 tumors with insufficient DNA for NGS and 1 
tumor with too few cells for FISH and IHC were included in 
the analysis as being without concomitant mutations.
DISCUSSION
Certain EGFR-mutated NSCLCs are inherently 
resistant to TKI-inhibitors and NSCLCs initially 
Patient 
no.
NSCLC 
histotype
EGFR-mutations^
(c.: cDNA sequence; p.: 
protein sequence)
MET-
amplification§
MET protein 
overexpression§§
TP53 
mutation Other mutations
16 ADC c.2573T>G, p.L858R
c.216Cdel, 
p.P74fs* 
(unknown)
PIK3CA: 
c.1633G>A, 
p.E545K 
(pathogenic)
17 ADC c.2240_2257del18, p.L747_P753delinsS
CTNNB1: c.98C>G, 
p.S33C (pathogenic)
18 ADC c.2235_2249del15, p.E746_A750delELREA
3+ in 100% of 
tumor cells
c.535C>T, 
p.H179Y 
(pathogenic)
19 ADC c.2236_2250del15, p.E746_A750delELREA
c.403T>G, 
p.C135G 
(pathogenic)
20 ADC c.2235_2249del15, p.E746_A750delELREA
c.376-1G>T 
(Substitution 
- intronic) 
(pathogenic)
FGFR1: 
c.373_374insTCA, 
p.S125-E126insS 
(unknown)
21 ADC c.2235_2249del15, p.E746_A750delELREA
22 ADC c.2573T>G, p.L858R CTNNB1: c.110C>T, p.S37F (pathogenic)
23 ADC c.2235_2249del15, p.E746_A750delELREA .
FGFR3: 
c.2349_2350delAG, 
p.D785fs*31 
(unknown)
ADC: Adenocarcinoma; SCC: Squamous cell carcinoma; ADSC: Adenosquamous carcinoma
In parenthesis the pathogenic prediction of the mutations according to the catalogue of somatic mutations in cancer 
(COSMIC) at http://cancer.sanger.ac.uk/cosmic. ^All identified EGFR-mutations were COSMIC-verified as being 
pathogenic.
§ For clarity only cases with some level of MET-amplification (high-, intermediate-, low-level) are shown; empty rows = no 
MET-amplification, as defined in Materials and methods.
§§ For clarity only cases with MET-overexpression (3+) and % of overexpressing cells are shown, empty rows = cases with 
MET-expression 2+, 1+ or 0, as defined in Materials and methods.
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responding will ultimately become TKI-resistant and 
progress. In our study, 7% (36/514) of tested NSCLCs of 
all stages and 8% (23/283) of NSCLCs in advanced stage 
harbored EGFR-mutations, consistent with previous data 
concerning Danish patients [15].
Among the advanced erlotinib-treated NSCLCs, 
one simultaneously carried the p.L858R and the intrinsic 
erlotinib-resistant p.T790M EGFR-mutations, but no 
mutations in other analyzed genes. Known as the most 
common mechanism of acquired resistance to first-/
second-generation EGFR-TKIs, p.T790M occurrence at 
baseline seems frequently associated with lack of OR and 
poor outcome in patients treated with these TKIs [3, 4]. 
Accordingly, our p.L858R/p.T790M case displayed no 
OR. Another erlotinib-treated case harbored the double 
p.G719C/p.S768I EGFR-mutation, each considered 
uncommon and reportedly less sensitive to gefitinib/
erlotinib than more common EGFR-mutations [16, 17]. 
Yet, p.G719C and p.S768I may coexist more frequently 
than other rare mutations in NSCLC [16, 18]. Moreover, 
patients with EGFR co-mutations exhibit shorter PFS 
and lower RR than patients with single EGFR-mutations 
[19]. Although S768I alone or concomitant with exon 
18 G719X does not necessarily appear to be sensitive to 
erlotinib [16, 17] it was shown to respond to afatinib [20, 
21]. Our p.G719C/p.S768I case also showed intermediate-
level of MET-amplification, MET-overexpression, and 
the fairly rare p.H168R TP53-mutation, nevertheless 
it did display an OR to erlotinib. Thus, given the rarity 
and variable response of TKI-treated cases with exon 20 
S768I, the exact prognostic and predictive role of this 
mutation in EGFR-mutant NSCLC seems still unclear. 
A separate EGFR-mutant NSCLC carried the unusual 
combination of the two rare mutations p.E746_R748del 
and p.A750P in EGFR exon 19, together with the 
p.T1010I point-mutation in the MET-gene. The sensitivity 
of these two exon 19-mutations to EGFR-TKIs is poorly 
described, while the MET-substitution has been reported 
to be associated with compromised response to these drugs 
[22]. In any case, this patient did show a partial response 
to erlotinib with PFS longer than 17 months. Another 
case displayed an EGFR exon 19-insertion resulting 
in 6 amino acid duplication (p.I744_K745insKIPVAI) 
together with a missense TP53-mutation and low-level 
MET-amplification. EGFR exon 19-insertions have been 
reported in only 0.26% and 0.11% of large Caucasian 
and Asian NSCLC-cohorts, respectively [23, 24], thus 
their response to EGFR-TKIs is uncertain. A recent meta-
analysis of the few reported patients with these mutations 
suggested that they had lower RR than patients with 
common EGFR-mutations, but incomplete PFS/OS data 
in this small cohort rendered difficult the comparison 
[24]. In this regard, our patient with exon 19-insertion 
showed no OR to erlotinib, but one cannot exclude that 
the concomitant TP53-mutation and possibly the low-level 
MET-amplification associated with MET-overexpression 
influenced this lack of response.
We also addressed whether possible co-mutations 
in alternative cancer-drivers could interfere with the 
response to erlotinib. In a previous exploratory study of 
Figure 1: Unusual double p.E746_R748del/p.A750P EGFR-mutation identified by NGS in one NSCLC-case (A; patient no. 9 in Table 2). 
Biopsy from NSCLC of ADC subtype with activating p.L858R EGFR-mutation (B; patient no. 5 in Table 2) identified by NGS, high-level 
MET-amplification detected by FISH (C; green, x100), and overexpression of MET receptor assessed by IHC (D; x10).
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197 consecutive NSCLC cases with TKI-sensitive EGFR-
mutations, 11 exhibited primary resistance to EGFR-
TKIs, but apart from three of these cases exhibiting either 
concomitant p.T790M, MET-amplification, or ALK-fusion, 
no other co-mutations in driver genes that could explain 
the intrinsic TKI-resistance were identified by targeted 
NGS [25]. Of the 21 erlotinib-treated NSCLCs that we 
assessed by targeted NGS, 71% exhibited concomitant 
mutations in alternative cancer-drivers before TKI-therapy. 
The most frequent were TP53-mutations found in 67% of 
these cases, whereas 60% of them harbored co-mutations 
in either MET, KRAS, SMAD4, PIK3CA, CTNNB1, NRAS, 
DDR2, ERBB4, FGFR1, or FGFR3. Using the same 
targeted NGS platform as ours, two other groups recently 
detected cases of advanced EGFR-mutant NSCLC that 
prior to gefitinib-treatment displayed co-mutations very 
similar to those identified in our study and at comparable 
frequency. Notably, these cases responded significantly 
worse to gefitinib than those without co-mutations [26, 
27].
Moreover, in a recent large database-study assessing 
characteristics and outcomes of patients harboring 
multiple molecular alterations, patients with EGFR/KRAS 
and EGFR/PIK3CA co-mutations experienced worse PFS 
during TKI-therapy than patients having only EGFR-
mutations [6]. Collectively, these results indicate that the 
concurrent mutations we have detected are among the 
most frequent in advanced therapy-naïve EGFR-mutant 
NSCLC and could be involved in primary resistance to 
gefitinib and erlotinib.
Mutant TP53 occurs in over 50% of pulmonary 
ADCs [8] and may interfere with TKI-induced cell-cycle 
arrest and apoptosis, thereby contributing to acquired TKI-
resistance development [28–31]. Regarding intrinsic TKI-
resistance, though, relatively small cohorts of gefitinib- 
or erlotinib-treated NSCLC-patients comparable to ours 
have shown only a marginal negative impact of coexisting 
TP53-mutations on the OR to TKIs [26, 27]. Similarly, we 
found no significant association between TP53-mutations 
and sensitivity to erlotinib. These findings may be due to 
stochastic variations related to relatively few observations 
and/or the type of identified TP53-mutations that may 
differently interfere with the effect of TKIs.
As for MET-status in the EGFR-mutated NSCLCs, 
we found 1 case with MET-mutation, four cases 
with different MET-amplification levels and MET-
overexpression, and one case with MET-overexpression 
not associated with amplification. The overall frequency 
(22.2%) of MET GCN gain in our cohort of EGFR-mutated 
cases was similar to that reported by Schildhaus et al. in 
their overall NSCLC population and subgroup of EGFR-
mutated tumors [11]. Also consistent with Schildhaus et 
al. [11], we found almost complete concordance between 
MET-amplification and MET-overexpression (4/5 cases). 
Furthermore, TP53-mutation occurred in 3/5 of patients 
with MET-amplification and/or MET-overexpression, 
suggesting possible growth advantages for NSCLCs 
that concomitantly have altered EGFR-, MET- and 
p53-dependent signaling. In preclinical models, MET-
amplification has been shown to be a driver for NSCLC 
growth and survival [32]. In the clinical setting 5-20% of 
NSCLC patients with acquired resistance to EGFR-TKIs 
have MET-amplification likely due to clonal selection 
by TKI-treatment of preexisting MET-amplified cells, 
resulting in activated MET-signaling, which bypasses 
EGFR-blockade and induces cell proliferation and survival 
[3, 4, 33]. Although this role of MET in acquired TKI-
resistance is well established, the potential impact on the 
intrinsic TKI-resistance is less clear [3, 4]. Single cases 
of NSCLC presenting with concomitant EGFR-mutation 
and de novo MET-amplification associated with primary 
resistance to erlotinib have been reported. Interestingly, 
these cases have shown response to a dual EGFR/MET 
blockade mediated by erlotinib/crizotinib combination 
[34, 35], thereby illustrating feasibility and therapeutic 
potential of combinatorial strategies in EGFR-mutant 
Figure 2: Progression free survival (A) and Overall survival (B) of 23 EGFR-mutation positive NSCLC patients with or without identified 
concomitant genetic aberrations.
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NSCLC with activation of bypass signaling pathways, 
such as MET-amplification. However, we found no 
indication in our cohort that MET-status at baseline 
inevitably hampered the efficacy of erlotinib-treatment. 
Only the case with EGFR exon 19-duplication (p.I744_
K745insKIPVAI) that concomitantly harbored a TP53-
mutation (p.T155P; classified as “neutral” in COSMIC) 
and low-level MET-amplification together with MET-
overexpression, did not respond to erlotinib (Tables 1 
and 2). The other four cases with MET-amplification and/
or MET-overexpression, two of which also had TP53-
mutations, as well as the case with MET-mutation, all 
partially responded to erlotinib (Tables 1 and 2). Although 
concurrent EGFR-mutation and ALK-rearrangement in 
lung ADC is more frequent than initially anticipated [7-
10, 36], we detected no ALK fusion-protein expression, 
i.e. no sign of ALK-rearrangement, in any of the 23 EGFR-
mutated patients. Consistent with the reported possibility 
of rare concomitance of EGFR- and KRAS-mutations 
in lung ADCs [7, 8, 12, 13], one of our EGFR-mutated 
cases harbored the p.G12V KRAS-mutant together with 
the p.R158L TP53-mutant, and somehow surprisingly it 
partially responded to erlotinib. KRAS-mutations are one 
of the most common genetic events in lung ADC and 
constitutively activate effectors downstream of EGFR, 
thus they can potentially cause TKI-resistance and be a 
negative predictive biomarker for response to EGFR-TKIs 
in NSCLC [37]. Nevertheless, the role of KRAS-mutations 
in intrinsic TKI-resistance remains unclear. Another of our 
cases partially responding to erlotinib displayed TP53- 
and PIK3CA-mutations concurrently with the activating 
p.L858R EGFR-mutant. Somatic mutations in the catalytic 
domain of PIK3CA have been implicated in acquired TKI-
resistance and also found in 1%–3% of NSCLCs prior 
to TKI therapy [38]. These PIK3CA-mutations render 
EGFR-mutant NSCLC cell lines resistant to EGFR-TKIs 
by activating AKT-signaling and inhibiting TKI-induced 
apoptosis [38]. In a large, retrospectively analyzed cohort 
of patients with advanced EGFR-mutant lung ADC, the 
concomitant occurrence of a PIK3CA-mutation was a 
negative prognostic factor associated with decreased 
median OS, but did not impact benefit from EGFR-TKI 
monotherapy in terms of objective RR, PFS and duration 
of response [39]. As our erlotinib-treated PIK3CA-
comutated case, these data suggest that PIK3CA-mutations 
despite being considered cancer-drivers do not necessarily 
represent a mechanism of primary resistance to erlotinib in 
EGFR-mutated NSCLC.
Two other patients partially responding to erlotinib 
displayed co-mutation of the CTNNB1 gene coding for 
β-catenin, the main effector in the Wnt/β-catenin signaling 
pathway that transactivates cell proliferation-related genes 
[40]. Interestingly, preclinical data show that β-catenin 
is activated by EGFR-mutants and contributes to the 
development of EGFR-mutated NSCLC, so that CTNNB1-
mutations can potentially induce resistance to EGFR-
TKIs [41–43]. Therefore, targeting the Wnt/β-catenin 
pathway might provide novel strategies to counteract TKI-
resistance [41]. However, the role of CTNNB1-mutations 
in TKI-resistance awaits further clinical confirmation.
Partial response to erlotinib was also seen in a case 
concomitantly revealing an EGFR exon 19-microdeletion, 
“pathogenic” mutations in TP53 and ERBB4 and 
“unknown”/unreported mutations in NRAS and DDR2 
(patient 15, Table 2). NRAS-mutations are detectable in 
~1% of NSCLCs, particularly ADCs in current/former 
smokers [44], but their role in TKI-resistance, despite 
being hypothetically similar to that of KRAS-mutations, 
is poorly explored. Missense mutations of DDR2, 
which encodes the collagen receptor discoidin domain 
receptor 2, are present in 4% of pulmonary SCCs and 
approximately 1.5% of ADCs (http://cancer.sanger.
ac.uk/cosmic). However, their frequency was reported 
increased to 16% in EGFR-mutated NSCLC, without 
significant impact on gefitinib-treatment [26]. ERBB4-
mutations occur in ~1% of NSCLCs (http://cancer.sanger.
ac.uk/cosmic). The observed p.S239P mutation resides 
in ERBB4 extracellular dimerizing domain, has formerly 
been reported in esophageal cancer as ERBB4-activating 
mutation [45] and might represent a bypass-mechanism 
for erlotinib-resistance, but the role of ERBB4-mutants in 
TKI-resistance needs further clarification. Finally, three 
of the 23 EGFR-mutant NSCLCs harbored a concomitant 
mutation in either SMAD4, FGFR1, or FGFR3. The 
former encodes the SMAD4 transcriptional co-factor 
that mediates TGF-β tumor-suppressive function by 
inducing growth arrest and apoptosis [46], but the 
incidence and function of inactivating SMAD4-mutations 
in TKI-resistance are scantly known. Recently SMAD4 
co-mutations were observed in EGFR-mutated NSCLCs 
especially occurring in gefitinib-sensitive patients [26, 27]. 
However, our patient with SMAD4 co-mutation exhibited 
mixed response to erlotinib. Thus, the significance of 
SMAD4-mutations in TKI-resistance remains unclear.
Constitutive FGFR1-activation by FGFR1-
amplification, -translocation or -mutation is associated 
with various malignancies. FGFR1-amplification has 
been observed in up to 20% of pulmonary SCCs and less 
frequently in ADCs and small-cell carcinomas [47]. Single 
preclinical and clinical studies suggest that activated 
FGFR1-signaling may represent a mechanism of acquired 
resistance to EGFR-TKIs [48–50]. Lim et al. reported 
that 2 of 20 EGFR-mutant NSCLCs not responding to 
gefitinib carried a concomitant FGFR1-mutation [26]. Our 
FGR1-mutated case concurrently displayed an intronic 
substitution in TP53 predicted to be “pathogenic” in 
COSMIC and nonetheless did show OR to TKI-treatment.
Activating FGR3-mutations have been reported 
in small fractions of advanced pulmonary SCCs and 
ADCs [51–53], including cases with co-existing EGFR-
mutations. Additionally, lung ADC may contain oncogenic 
FGFR3-TACC3 fusions that may function as bypass-
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mechanism associated with intrinsic/acquired resistance 
to EGFR-TKIs reversible by FGFR-inhibitors [54–56]. 
As we recently described elsewhere, our advanced EGFR-
mutant ADC-case with concomitant FGFR3-mutation 
displayed mixed response, with pleural metastasis 
progressing already 7 weeks after initiating first-line 
erlotinib-treatment, whereas other metastatic sites 
progressed only 6 months later after acquiring additional 
p.T790M EGFR-mutation [57].
Somehow surprisingly, among our 23 EGFR-
mutated patients treated with erlotinib, 17 showed OR 
(complete/partial) regardless of the presence of cancer-
relevant co-mutations that can potentially represent 
mechanisms of primary resistance to EGFR-TKIs, 
because they occurred in genes coding for proteins that 
either are directly downstream the EGFR or belong to 
alternative by-pass pathways, as discussed above. No 
statistically significant difference in PFS or OS was 
observed when stratifying according to concomitant 
driver status, potentially due to the low number of patients 
included (Figure 2). Although concurrent aberrations in 
other driver genes did not seem to significantly impair 
erlotinib efficacy in most of our cases, they could 
potentially decrease the time to progression by serving as 
alternative driver-pathways. Once treated with erlotinib, 
NSCLCs may become resistant either by selecting pre-
existing subclones carrying resistance-mutations such as 
p.T790M or possessing the ability to depend on alternative 
oncogenic pathways for survival [3, 58]. Thus, acquired 
TKI-resistance may already exist in subclones at baseline 
and targeting a single activating driver mutation will 
eventually lead to treatment failure, while combining 
different pathway-targeted drugs based on pre-treatment 
molecular analyses could potentially be applied in 
NSCLC to avert or postpone the appearance of resistant 
tumor cells. In this regard, our study presents limitations, 
such as the fairly low number of investigated EGFR-
mutated cases and the fact that the utilized techniques 
(NGS, FISH, IHC) covered only a specified number of 
driver genes. In contrast, the optimal implementation of 
combination targeted therapy for NSCLC in the future 
will also require broader knowledge of other genetic or 
epigenetic events that potentially can represent additional 
targets or resistance mechanisms and thereby serve as 
predictive biomarkers as well. This will obviously add 
to the complexity of combinatorial therapeutic strategies, 
nevertheless, implementing broad genomic sequencing 
panels, such as the recently reported MSK-IMPACT 
assay, can detect multiple potentially actionable targets 
coexisting within individual tumors in a significant 
amount of patients, further underlining the future need of 
combination therapies against NSCLC [5].
In conclusion, the vast majority of advanced EGFR-
mutated NSCLCs in our cohort showed co-mutations 
in other cancer driver genes before receiving first-line 
erlotinib-treatment. These concurrent alternative mutations 
may not necessarily lead to initial resistance to erlotinib 
but they may impact the time to progression to first-line 
TKI-treatment and represent potential therapeutic targets 
for combined targeted therapy.
MATERIALS AND METHODS
Tumor samples and mutation analysis
Five hundred and fourteen consecutive NSCLCs of 
all stages diagnosed at our institution from July 2013 to 
August 2015 were included. All tumors of non-squamous 
cell type were examined, while squamous cell carcinomas 
(SCCs) were only tested on specific clinical indication 
(patients younger than 50 years or never smokers/
light smokers with less than 2 pack-years). DNA was 
extracted from two 5-μm-thick formalin-fixed paraffin-
embedded (FFPE) tissue sections of diagnostic biopsies 
or from smears of cytological samples obtained from the 
primary tumor or metastases in lymph nodes or distant 
organs. Samples diagnosed as ADCs and judged suitable 
(minimal relative tumor cell nuclei content of 20%) were 
routinely tested for EGFR-mutations using the Cobas® 
EGFR Mutation Test (Roche Diagnostics) on the Cobas 
z480 analyzer (analytical sensitivity of 5%) according 
to the supplier´s instructions. This fully automated 
analysis covers 41 EGFR-mutations, including G719X 
(G719A, G719C, or G719S) in exon 18, 29 variable exon 
19-microdeletions, S768I and T790M in exon 20, five 
different exon 20-insertions, and L858R in exon 21 (two 
variants).
Specimens below the 20% cut-off were enriched for 
tumor content using manual micro-dissection.
Samples from EGFR-mutated NSCLC patients that 
were candidate for first-line TKI treatment (advanced 
stage, PS 0-2) were further tested by next generation 
sequencing (NGS) for other possible simultaneous 
cancer-relevant gene mutations and for confirming and 
specifying the type of EGFR-mutations detected by 
Cobas® Test, whereas cases not eligible to TKI therapy 
(low stage/operable or receiving chemo-radiotherapy, 
PS 3, or deceased before therapy start) were not further 
analyzed. For each FFPE specimen, 10 ng of genomic 
DNA, purified by the QIAamp DNA Minikit (Qiagen) 
and quantified by the Qubit® dsDNA HS assay on a 
Qubit® 2.0 Flourometer (Thermo Fisher Scientific), 
were used for library preparation with the Ion AmpliSeq 
Library Kit 2.0 (LifeTechnologies) and the Ion AmpliSeq 
Colon-Lung Cancer Research Panel v2 (Ion Torrent, 
Thermo Fisher Scientific). This panel yields 92 amplicons 
covering 504 mutational hot-spot regions and 1825 hot-
spot mutations in the following 22 lung/colon cancer-
associated genes: AKT1 (NCBI reference sequence: 
NM_005163), ALK (NM_004304), BRAF (NM_004333), 
CTNNB1 (NM_001904), DDR2 (NM_001014796), 
EGFR (NM_005228), ERBB2 (NM_004448), ERBB4 
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(NM_005235), FBXW7 (NM_033632), FGFR1 
(NM_023110), FGFR2 (NM_022970), FGFR3 
(NM_000142), KRAS (NM_033360), MAP2K1 
(NM_002755), MET (NM_001127500), NOTCH1 
(NM_017617), NRAS (NM_002524), PIK3CA 
(NM_006218), PTEN (NM_000314), SMAD4 
(NM_005359), STK11 (NM_000455) and TP53 
(NM_000546). Library concentration was determined by 
the Ion Ampliseq™ TaqMan Quantification Kit.
Preparation of sequencing templates and Ion Spheres 
followed by loading on Ion 316 chips v2 was automatically 
performed on the Ion Chef System (Thermo Fisher 
Scientific). Sequencing was carried out on an Ion Torrent 
Personal Genome™ (PGM) sequencer using the Ion PGM 
Sequencing 200 Kit v2 according to the manufacturer’s 
instructions. Data analysis, including alignment to the 
hg19 human reference genome and variant calling, was 
performed by the Torrent Suite Software v.4.4 (Thermo 
Fisher Scientific) and visually verified with the Integrative 
Genomics Viewer; IGV v.2.1 (Broad Institute)
Fluorescence in-situ hybridization (FISH) and 
immunohistochemistry (IHC)
FISH was utilized to detect possible MET-
amplification, which can represent a mechanism of TKI-
resistance [59].
Two-μm-thick FFPE tissue sections from biopsies 
or cell-blocks of cytological samples were hybridized 
overnight with the Zyto-Light SPEC MET/CEN7 Dual 
Color Probe (ZytoVision) that detects the MET-gene 
and the centromeric portion of the MET-harboring 
chromosome 7, as previously described with minor 
modifications [11].
Briefly, slides were scanned using a X63 objective 
and appropriate filter sets (DM5500 fluorescent 
microscope; Leica), using normal fibroblasts, leukocytes, 
endothelial cells or non-neoplastic lung tissue as internal 
controls and individually analyzing 100 tumor cell nuclei 
(20 neighboring tumor cell nuclei from five random areas 
of homogenous distribution of MET signals) with the 
X100 objective counting MET (green) and CEN7 (orange) 
signals. FISH was assessed by one reader (ES-R) without 
knowing the IHC data. The tumor samples were classified 
into the following four groups of MET-amplification status 
[11].
A) High-level amplification when they displayed 
a MET/CEN7 ratio ≥2.0 or an average MET gene copy 
number (GCN) per cell of ≥6.0 or ≥10% of tumor cells 
containing ≥15 MET signals. B) Intermediate-level 
of GCN gain when ≥50% of cells contained ≥5 MET 
signals and the criteria for high-level amplification were 
not fulfilled. C) Low-level of GCN gain when ≥40% of 
tumor cells showed ≥4 MET signals and criteria for high-/
intermediate-level amplification were not fulfilled. D) 
Negative (no amplification/GCN gain) when none of the 
above criteria were fulfilled.
IHC for membranous and cytoplasmic expression 
of MET-receptor was performed on FFPE 2.5-μm-thick 
tissue sections using a BenchMark ULTRA automated 
slide immunostainer (Ventana Medical Systems Inc.; item 
no. N750-BMKU-FS), Ultra Cell Conditioning solution 
(CC1) pretreatment (Ventana) for 8 min at 95°C, four 
CC1 treatments (20, 36, 52, and 64 min), and incubation 
with the pre-diluted CONFIRM anti-Total c-MET (SP44) 
Rabbit mAb (Ventana Medical Systems, Inc.; Cat. # 
790-4430) for 16 min, as described [11]. The reaction 
was visualized using ultraView DAB Detection Kit and 
hematoxylin counterstaining (Ventana). MET expression 
was scored in a blinded manner (without knowing the 
FISH results) by one observer (ES-R), assessing staining 
intensity (negative, weak, moderate, or strong) and the 
percentage of cells with these intensities using bronchial/
alveolar epithelial cells as internal controls for weak-
moderate intensity. Thereby, 4 diagnostic “immunoscores” 
were defined: 3+/overexpression (strong intensity in ≥50% 
of tumor cells); 2+ (moderate intensity in ≥50% of tumor 
cells); 1+ (weak intensity in ≥50% of tumor cells); and 
0 (no staining or <50% of tumor cells stained with any 
intensity) [11].
For ALK immunostaining, as indicator of ALK-
rearrangement [60], the fully automated IHC assay using 
the pre-diluted VENTANA anti-ALK (D5F3) Rabbit 
mAb (Ventana Medical Systems Inc.; Cat. # 790-4794) 
was used together with the Optiview DAB IHC detection 
kit and Optiview Amplification kit on the Benchmark XT 
stainer (Ventana Medical Systems Inc.), implementing a 
binary scoring system (present/absent moderate/strong 
granular cytoplasmic staining in any percentage of tumor 
cells) according to manufacturer’s instructions [11, 60].
Each case was also stained with an unrelated 
matched rabbit IgG mAb used as negative control. Samples 
with known MET-amplification and MET-overexpression 
or ALK--rearrangement and ALK-overexpression were 
used as positive controls [61].
Assessment of tumor response and definition of 
lack of response/intrinsic resistance
Objective response (OR) evaluation was done by 
CT-scan at baseline (maximum 1 month prior to TKI-
treatment start), followed by CT-scans every 9 weeks. 
RECIST v1.1 criteria for definitions of response and 
progression were used [62]. Patients who progressed 
within 18 weeks (4 months) were classified as having 
intrinsic resistance.
Statistical analysis
Overall survival (OS) was defined as the time 
from onset of treatment to the time of death from any 
cause or last follow-up. PFS was defined as the time 
from onset of treatment with erlotinib to a documented 
progression or death from any cause. For patients without 
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any progression at the time of analysis, the date of last 
follow-up was considered right-censored. Kaplan-Meier 
curves were used to estimate curves for OS and PFS and 
chi-square test was used for comparison of proportions. 
A p-value < 0.05 was considered statistically significant.
The study was approved by the institutions’ local 
ethical committee and was with data collection on pre-
defined case report forms.
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